Developer docs
API playgroundTry for free, no card

Search company profiles

Digitalis Ventures

Full company profile

uuid0000ag9

Namestring
Digitalis Ventures
Legal namestring
Digitalis Ventures
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Digitalis Ventures is a privately-held venture capital firm headquartered at 11 Times Square, New York, that invests in early-stage companies solving complex problems in human and animal health. Founded by Geoffrey W. Smith, the firm operates as the venture capital arm of The Digitalis Group, alongside Digitalis Commons (a non-profit building public-interest health technology), Digitalis Labs (designing novel biomedicine and health technologies), and Digitalis Research. The firm runs two principal programs: a Human Health program covering Life Sciences (biotechnology companies leveraging breakthrough science, e.g., EpiBiologics, Terray Therapeutics, Judo Bio, Switch Therapeutics, T-Therapeutics, Bonum Therapeutics) and Health Technologies (access, cost, and outcomes plays such as Clasp, Findhelp, Expressable, CandidPro, Positive Development, Varda, Reema Health, Ansel, Elemental Machines, Helm Health); and an Animal Health program operated through the Companion Funds in partnership with Mars Petcare, which gives portfolio companies access to 70,000+ Mars associates, 2,500+ clinics and labs, and operations across 130+ countries (portfolio includes Gallant, Rejuvenate Bio, Astra Therapeutics, Scratchpay, Native Pet, PetMedix, Honor Pet, Oncura). The Animal Health program additionally co-runs the Leap Venture Studio accelerator with Michelsen Found Animals and R/GA Ventures for earliest-stage pet health founders.

The firm generates revenue through standard venture fund economics: management fees on committed capital and carried interest on fund returns. Digitalis reports aggregate assets under management exceeding $800 million, anchored by the $300 million Companion Fund II launched with Mars Petcare in October 2023. Management fee rates, carried interest terms, fund minimums, and full LP composition are not publicly disclosed. As of the source data, Digitalis manages capital from offices and investor presence in New York City (HQ), Boston, Los Angeles, San Francisco, Gainesville, and Zurich, with a 16-person team comprising two Managing Partners (Geoffrey W. Smith; Misti Ushio, ex-TARA Biosystems CEO and ex-Merck), four Partners (Samuel Bjork, Amit Bansal, Ben Jacobs, Drew Taylor as Venture Partner), two Technical Partners (Dac Nguyen, Cindy Cole DVM PhD), a Principal (Travis Hughes, MD-PhD), three Associates, and finance staff. The firm actively publishes investment thesis content via the Digitalis Notebook (monthly Notes on Engineering Health; bimonthly Notes on Animal Health).

Short descriptiontext

Digitalis Ventures is a New York-based venture capital firm that invests early-stage capital in human and animal health companies across life sciences, health technologies, and pet health, managing over $800M and co-managing the Companion Funds with Mars Petcare.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital investing, life sciences venture capital, animal health investing, biomedicine investments, health technology funding
Industry2 codes
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSAEALAC
Venture Capital Fundraising Placement
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation
NAICS code1 code
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture capital fund management
TypeManaged Services
Description

Digitalis Ventures manages venture capital funds (including the Companion Funds with Mars Petcare) that invest in early-stage companies across human and animal health; as a VC firm, revenue is generated through typical fund economics including management fees on committed capital and carried interest (carried interest / promote) on fund returns, with capital deployed across multiple portfolio companies and reinvested in subsequent rounds.

digitalisventures.com
Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Companion Funds
Description

Digitalis Ventures' branded fund vehicles that invest in animal health companies in partnership with Mars Petcare, leveraging Mars Petcare's operational experience and global footprint across more than 130 countries.

digitalisventures.com
Core offering1 text field

Digitalis Ventures is a venture capital firm that provides early-stage equity financing to companies solving complex problems in human and animal health. It operates two primary investment programs—a Human Health program (Life Sciences and Health Technologies) and an Animal Health program executed through Companion Funds in partnership with Mars Petcare—supplemented by the Leap Venture Studio accelerator for earliest-stage pet health founders.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Digitalis Ventures is a single venture capital platform (not a packaged SaaS product) that invests across two primary program areas — Human Health (Life Sciences and Health Technologies) and Animal Health (operated through the Companion Funds in partnership with Mars Petcare, with the Leap Venture Studio accelerator for earliest-stage founders). The Human Health program backs biotechnology and technology-enabled healthcare companies (e.g., EpiBiologics, Terray Therapeutics, Faeth Therapeutics, Clasp, Elemental Machines, Findhelp), while the Animal Health program backs pet health startups (e.g., Rejuvenate Bio, Gallant, Astra Therapeutics, Scratchpay, Native Pet, PetMedix). The platform is part of the broader Digitalis Group, which also encompasses Digitalis Commons (a non-profit building public-interest health technology) and Digitalis Labs (designing novel biomedicine and health technologies), with related content published through the Digitalis Notebook.

Product and service3 records
1Digitalis Ventures Human Health Investing Program
CategoryInvestment fund
Description

Venture capital program investing in early-stage biotechnology companies leveraging breakthrough science to improve human health, and in technology-enabled solutions that improve access to care, outcomes, and cost; includes Life Sciences and Health Technologies sub-portfolios.

2Digitalis Ventures Animal Health / Companion Funds
CategoryInvestment fund
Description

Venture capital program, operated in partnership with Mars Petcare, that invests in companies leveraging science, technology, and design to improve animal health; includes the Companion Funds vehicle and the Leap Venture Studio accelerator with Michelsen Found Animals and R/GA Ventures.

3Leap Venture Studio
CategoryAccelerator program
Description

Accelerator program, run in partnership with Michelsen Found Animals and R/GA Ventures, that serves earliest-stage pet health founders and provides Digitalis Ventures with a structured deal-flow channel in animal health.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large early-stage venture firm with a meaningful health and biotech investing practice — comparable in early-stage, science-led thesis but materially broader in scope (consumer, deep tech, climate).

TypeDirect peer
Description

Long-established venture capital firm investing primarily in early-stage biotechnology and life sciences companies — directly comparable to Digitalis's Life Sciences book on breakthrough science and platform biology.

TypeDirect peer
Description

Biotech creation engine that originates and funds platform biotech companies — closely comparable to Digitalis's investment in breakthrough human-health science and its technical bench-driven sourcing model.

TypeDirect peer
Description

Early-stage venture firm investing at the intersection of science, technology, and health — directly comparable in thesis (frontier science + tech-enabled health) and stage (early-stage).

TypeDirect peer
Description

Venture firm founded by Bill Maris focused on health-tech, biotech, and frontier science — directly comparable to Digitalis in both Human Health verticals and in stage and check size.

TypeDirect peer
Description

a16z Bio/Health funds invest in biotech, digital health, and health-tech companies — directly comparable in human-health investing mandate, although a16z operates at materially larger AUM and broader scope.

TypeBroad incumbent
Description

GV's life sciences team co-led the $107M EpiBiologics Series B with Digitalis participating — comparable in life-sciences investing mandate, though GV is a much larger, generalist fund.

TypeDirect peer
Description

Biotech-focused venture firm investing across oncology and platform biology — directly comparable to Digitalis's Human Health life sciences book on early-stage therapeutic platforms.

TypeBroad incumbent
Description

Healthcare-dedicated investment firm across venture, growth, and credit — broadly comparable in health-only mandate, but at significantly larger AUM and across all stages.

TypeRegional player
Description

Animal-health focused venture fund — overlaps directly with Digitalis's Companion Funds platform as a peer in the niche pet/animal-health VC category, though independent rather than a Mars-co-managed vehicle.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment123 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Digitalis Ventures

Venture Capitaldigitalisventures.com

Digitalis Ventures is a New York-based venture capital firm that invests early-stage capital in human and animal health companies across life sciences, health technologies, and pet health, managing over $800M and co-managing the Companion Funds with Mars Petcare.

What Digitalis Ventures does

Digitalis Ventures is a privately-held venture capital firm headquartered at 11 Times Square, New York, that invests in early-stage companies solving complex problems in human and animal health. Founded by Geoffrey W. Smith, the firm operates as the venture capital arm of The Digitalis Group, alongside Digitalis Commons (a non-profit building public-interest health technology), Digitalis Labs (designing novel biomedicine and health technologies), and Digitalis Research. The firm runs two principal programs: a Human Health program covering Life Sciences (biotechnology companies leveraging breakthrough science, e.g., EpiBiologics, Terray Therapeutics, Judo Bio, Switch Therapeutics, T-Therapeutics, Bonum Therapeutics) and Health Technologies (access, cost, and outcomes plays such as Clasp, Findhelp, Expressable, CandidPro, Positive Development, Varda, Reema Health, Ansel, Elemental Machines, Helm Health); and an Animal Health program operated through the Companion Funds in partnership with Mars Petcare, which gives portfolio companies access to 70,000+ Mars associates, 2,500+ clinics and labs, and operations across 130+ countries (portfolio includes Gallant, Rejuvenate Bio, Astra Therapeutics, Scratchpay, Native Pet, PetMedix, Honor Pet, Oncura). The Animal Health program additionally co-runs the Leap Venture Studio accelerator with Michelsen Found Animals and R/GA Ventures for earliest-stage pet health founders.

The firm generates revenue through standard venture fund economics: management fees on committed capital and carried interest on fund returns. Digitalis reports aggregate assets under management exceeding $800 million, anchored by the $300 million Companion Fund II launched with Mars Petcare in October 2023. Management fee rates, carried interest terms, fund minimums, and full LP composition are not publicly disclosed. As of the source data, Digitalis manages capital from offices and investor presence in New York City (HQ), Boston, Los Angeles, San Francisco, Gainesville, and Zurich, with a 16-person team comprising two Managing Partners (Geoffrey W. Smith; Misti Ushio, ex-TARA Biosystems CEO and ex-Merck), four Partners (Samuel Bjork, Amit Bansal, Ben Jacobs, Drew Taylor as Venture Partner), two Technical Partners (Dac Nguyen, Cindy Cole DVM PhD), a Principal (Travis Hughes, MD-PhD), three Associates, and finance staff. The firm actively publishes investment thesis content via the Digitalis Notebook (monthly Notes on Engineering Health; bimonthly Notes on Animal Health).

Digitalis Ventures firmographics

Firmographics
Name
Digitalis Ventures
Legal name
Digitalis Ventures
Website
https://digitalisventures.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Digitalis Ventures is a New York-based venture capital firm that invests early-stage capital in human and animal health companies across life sciences, health technologies, and pet health, managing over $800M and co-managing the Companion Funds with Mars Petcare.
Ownership category
akta.pro rank

Digitalis Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSAEALAC
Venture Capital Fundraising Placement
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation

Keywords

  • Venture capital investing
  • Life sciences venture capital
  • Animal health investing
  • Biomedicine investments
  • Health technology funding

Where Digitalis Ventures is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Digitalis Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture capital fund management: Digitalis Ventures manages venture capital funds (including the Companion Funds with Mars Petcare) that invest in early-stage companies across human and animal health; as a VC firm, revenue is generated through typical fund economics including management fees on committed capital and carried interest (carried interest / promote) on fund returns, with capital deployed across multiple portfolio companies and reinvested in subsequent rounds.

Go-to-market motion3 records

Digitalis Ventures product offering

Product offering

Core offering

Digitalis Ventures is a venture capital firm that provides early-stage equity financing to companies solving complex problems in human and animal health. It operates two primary investment programs—a Human Health program (Life Sciences and Health Technologies) and an Animal Health program executed through Companion Funds in partnership with Mars Petcare—supplemented by the Leap Venture Studio accelerator for earliest-stage pet health founders.

Product overview

Digitalis Ventures is a single venture capital platform (not a packaged SaaS product) that invests across two primary program areas — Human Health (Life Sciences and Health Technologies) and Animal Health (operated through the Companion Funds in partnership with Mars Petcare, with the Leap Venture Studio accelerator for earliest-stage founders). The Human Health program backs biotechnology and technology-enabled healthcare companies (e.g., EpiBiologics, Terray Therapeutics, Faeth Therapeutics, Clasp, Elemental Machines, Findhelp), while the Animal Health program backs pet health startups (e.g., Rejuvenate Bio, Gallant, Astra Therapeutics, Scratchpay, Native Pet, PetMedix). The platform is part of the broader Digitalis Group, which also encompasses Digitalis Commons (a non-profit building public-interest health technology) and Digitalis Labs (designing novel biomedicine and health technologies), with related content published through the Digitalis Notebook.

Differentiator

Problem solved

Functional benefit

Brands

  • Companion Funds: Digitalis Ventures' branded fund vehicles that invest in animal health companies in partnership with Mars Petcare, leveraging Mars Petcare's operational experience and global footprint across more than 130 countries.

Products and services

  • Digitalis Ventures Human Health Investing Program Venture capital program investing in early-stage biotechnology companies leveraging breakthrough science to improve human health, and in technology-enabled solutions that improve access to care, outcomes, and cost; includes Life Sciences and Health Technologies sub-portfolios.
  • Digitalis Ventures Animal Health / Companion Funds Venture capital program, operated in partnership with Mars Petcare, that invests in companies leveraging science, technology, and design to improve animal health; includes the Companion Funds vehicle and the Leap Venture Studio accelerator with Michelsen Found Animals and R/GA Ventures.
  • Leap Venture Studio Accelerator program, run in partnership with Michelsen Found Animals and R/GA Ventures, that serves earliest-stage pet health founders and provides Digitalis Ventures with a structured deal-flow channel in animal health.

Companies that use Digitalis Ventures

Customer profile

Ideal customer profiles2 records

Digitalis Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Digitalis Ventures partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights3 records

Digitalis Ventures competitors and assessment

Company assessment

Broad incumbents

  • Khosla Ventures: Large early-stage venture firm with a meaningful health and biotech investing practice — comparable in early-stage, science-led thesis but materially broader in scope (consumer, deep tech, climate).
  • GV (Google Ventures): GV's life sciences team co-led the $107M EpiBiologics Series B with Digitalis participating — comparable in life-sciences investing mandate, though GV is a much larger, generalist fund.
  • OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth, and credit — broadly comparable in health-only mandate, but at significantly larger AUM and across all stages.

Direct peers

  • ARCH Venture Partners: Long-established venture capital firm investing primarily in early-stage biotechnology and life sciences companies — directly comparable to Digitalis's Life Sciences book on breakthrough science and platform biology.
  • Flagship Pioneering: Biotech creation engine that originates and funds platform biotech companies — closely comparable to Digitalis's investment in breakthrough human-health science and its technical bench-driven sourcing model.
  • Lux Capital: Early-stage venture firm investing at the intersection of science, technology, and health — directly comparable in thesis (frontier science + tech-enabled health) and stage (early-stage).
  • Section 32: Venture firm founded by Bill Maris focused on health-tech, biotech, and frontier science — directly comparable to Digitalis in both Human Health verticals and in stage and check size.
  • Andreessen Horowitz (a16z Bio + Health): a16z Bio/Health funds invest in biotech, digital health, and health-tech companies — directly comparable in human-health investing mandate, although a16z operates at materially larger AUM and broader scope.
  • MPM Capital: Biotech-focused venture firm investing across oncology and platform biology — directly comparable to Digitalis's Human Health life sciences book on early-stage therapeutic platforms.

Regional players

  • Companion Fund: Animal-health focused venture fund — overlaps directly with Digitalis's Companion Funds platform as a peer in the niche pet/animal-health VC category, though independent rather than a Mars-co-managed vehicle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Digitalis Ventures social profiles

Digital presence

Digitalis Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Digitalis Ventures leadership team

Management profile

Number of profiles

Profiles1 record

Digitalis Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Digitalis Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Digitalis Ventures M&A and investment

M&A and investment

M&A

Investments123 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digitalis Ventures

What does Digitalis Ventures do?

Digitalis Ventures is a venture capital firm that provides early-stage equity financing to companies solving complex problems in human and animal health. It operates two primary investment programs—a Human Health program (Life Sciences and Health Technologies) and an Animal Health program executed through Companion Funds in partnership with Mars Petcare—supplemented by the Leap Venture Studio accelerator for earliest-stage pet health founders.

Is Digitalis Ventures a public or private company?

Digitalis Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Digitalis Ventures founded?

Digitalis Ventures was founded in 2016. It employs 11 to 50 people.

Where is Digitalis Ventures based?

Digitalis Ventures is headquartered in New York, United States, in the North America region.

How does Digitalis Ventures make money?

One revenue line is on record: venture capital fund management.

Who are Digitalis Ventures's main competitors?

Broad incumbents on record are Khosla Ventures, GV (Google Ventures) and OrbiMed Advisors. Direct peers are ARCH Venture Partners, Flagship Pioneering, Lux Capital, Section 32, Andreessen Horowitz (a16z Bio + Health) and MPM Capital. Companion Fund is listed as a regional player.

Does Digitalis Ventures have an API?

No public API is recorded for Digitalis Ventures.

What industry is Digitalis Ventures in?

Digitalis Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANACAA, Technology & Software Growth Equity, with a secondary code of FSAEALAC, Venture Capital Fundraising Placement. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebrazziYapay zeka destekli biyoteknoloji şirketi Enveda, 311 milyon dolar yatırım aldıEnveda, an AI-backed biotech, raised $311 million in a Series E round led by Catalio Capital Management. The funds will advance clinical trials of drug candidates and develop its PRISM platform and lab infrastructure. The company, founded in 2019, has raised $845 million total.FinSMEsEnveda Raises $311M in Series E FundingEnveda, a Boulder-based AI drug discovery platform, raised $311M in Series E funding led by Catalio Capital Management. The round brings total funding to over $845M, to be used for advancing ENV-294 and ENV-308 into later-stage trials and scaling PRISM.Venture Capital Access OnlineEnveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st CenturyEnveda closed a $311 million Series E financing led by Catalio Capital Management, with participation from Durable Capital Partners, ICONIQ, Lightspeed, and others. The proceeds will advance ENV-294 and ENV-308 into later-stage trials and scale its PRISM platform. The company's total capital raised since inception now exceeds $845 million.StartUp BeatHong Kong’s Buddy Bites lands $4.2 million Series A from Digitalis Ventures, eyes cat food and TaiwanBuddy Bites closed a $4.2 million Series A led by Digitalis Ventures, its first such round. The Hong Kong pet food company reports annual recurring revenue past $6 million and plans to launch cat food and expand into Taiwan.FinSMEsBuddy Bites Raises $4.2M in Series A FundingBuddy Bites, a Hong Kong-founded pet nutrition and e-commerce platform, raised $4.2M in Series A funding led by Digitalis Ventures. The company will use the capital to expand into Taiwan, scale its cat food line, and accelerate R&D for shelf-stable fresh dog food.FinSMEsOmni Raises $14.6M in Series A FundingOmni, a UK-based pet food developer, raised $14.6M in Series A funding co-led by IW Capital and Redrice Ventures. The company will use the capital to expand retail distribution in the UK, develop functional products, and run consumer marketing campaigns.StartupmagFoodtech startup Omni Pet raises £11m led by IW Capital with Redrice VenturesOmni Pet, a veterinary-grade foodtech startup, raised £11m in a growth round led by IW Capital with Redrice Ventures. The funding will accelerate online customer acquisition, retail expansion, and launch of a drug-free dog weight-loss supplement. The company reports over 100,000 customers and 200% sales growth since its Dragons' Den appearance.ThegrocerOmni secures £11m investment to back ‘Ozempic for dogs’ launchOmni raised £11m in a funding round led by IW Capital, with Deborah Meaden reinvesting. The pet nutrition company will use the funds to accelerate online customer acquisition, expand into retail, and launch an Ozempic-style natural weight-loss supplement for dogs. The business has grown over tenfold since its Dragons' Den appearance.pharmaphorumWhich biotechs have raised new VC financing this week?Triveni Bio raised $65 million in a Series C round to fund a phase 2 trial of its TRIV-573 candidate for atopic dermatitis. Cellares added $50 million to its Series D, bringing total funding to $327 million, while HMNC raised $50 million for phase 3 trials of depression drugs. Vedana and Neion Bio also raised $46 million and $23 million respectively.PR NewswireLifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal HealthRejuvenate Bio closed a $6 million financing round led by VCapital and announced an R&D collaboration with Merck Animal Health. The funds will support its gene therapy platform for chronic and age-related diseases in companion animals. The collaboration aims to advance a novel gene therapy program using Rejuvenate Bio's proprietary platform.